首頁 > 市場調查報告書 > 製藥

藥物開發開發業務受託機關

生物製藥CMO/CRO市場規模、佔有率和成長分析（按供應來源、服務類型、產品和地區分類）－產業預測（2026-2033年）

市場調查報告書

商品編碼

1900171

生物製藥CMO/CRO市場規模、佔有率和成長分析（按供應來源、服務類型、產品和地區分類）－產業預測（2026-2033年）

Biopharmaceutical CMO & CRO Market Size, Share, and Growth Analysis, By Source (Mammalian, Non-mammalian), By Service Type (Contract Manufacturing, Contract Research), By Product, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月16日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球生物製藥 CMO/CRO 市場預計到 2024 年將達到 343.1 億美元，從 2025 年的 363.4 億美元成長到 2033 年的 574.8 億美元，在預測期（2026-2033 年）內複合年成長率為 5.9%。

受消費者對創新治療方法需求不斷成長的推動，生物製藥產業正經歷顯著成長。契約製造組織 (CMO) 和受託研究機構(CRO) 在支援製藥公司方面發揮關鍵作用，前者透過外包生產運營，後者則提供全面的研究服務。這一趨勢凸顯了資源密集型流程（包括整個生物製造流程）外包的趨勢，並推動了對合約服務的需求。透過併購整合生物製程能力，使 CMO 能夠提供精簡的解決方案，從而加速產品上市。對一體化生產的投資進一步加強了該行業，旨在提高生產力和效率的策略聯盟便是明證。總體而言，CMO 和 CRO 在生物製藥行業中扮演關鍵角色，佔據了全球製藥市場 20% 以上的佔有率。

生物製藥CMO/CRO市場促進因素

生物製藥產業正經歷一場旨在增強競爭力並拓展契約製造和服務業務的整合浪潮。隨著新型治療方法和創新生物程序技術的湧現，合約生物生產公司面臨著適應不斷變化的市場動態的壓力。為了滿足相關人員和消費者多樣化的需求，替代性經營模式正變得越來越普遍。此外，生產設施中一次性使用系統的應用預計將顯著提高產能。這些因素共同為生物製藥CMO和CRO市場帶來了強勁的成長潛力，並在全球市場格局中創造了新的機會。

生物製藥CMO/CRO市場面臨的限制

儘管生物製藥CMO/CRO市場相比製藥CMO產業利潤率更高，但其成長潛力仍面臨許多限制因素。其中一個關鍵挑戰是需要對生產設施和先進設備進行大量投資，以加速生物製藥流程。此外，許多成熟的生物製藥公司不願完全採用外包模式，這進一步限制了市場擴張。另外，由於法規環境複雜且服務本身也較為複雜，CMO與客戶之間的談判也可能充滿挑戰。智慧財產權、保密性和擔保等問題增加了客戶與CMO簽訂合約的難度，進一步阻礙了市場成長。

生物製藥CMO/CRO市場趨勢

生物製藥CMO/CRO市場呈現顯著上升趨勢，這主要得益於企業對新產品開發的日益重視、研發活動的持續拓展以及策略聯盟的建立。隨著企業面臨研發效率下降和研發成本上升的挑戰，CMO/CRO正成為加速產品商業化的關鍵合作夥伴。地域擴張、併購以及強化分銷網路等成長策略對於企業獲取競爭優勢至關重要。這種不斷變化的市場格局促使生物製藥企業更加依賴合約組織，從而為生物製藥行業的持續市場成長和創新鋪平了道路。

Lonza Group（Switzerland）
Thermo Fisher Scientific（United States）
Catalent（United States）
WuXi Biologics（China）
Samsung Biologics（South Korea）
IQVIA（United States）
Syneos Health（United States）
ICON Plc（Ireland）
Medpace Holdings（United States）
Charles River Laboratories（United States）
PPD（United States）
Labcorp Drug Development（United States）
Parexel International（United States）
PRA Health Sciences（United States）
BioNTech SE（Germany）
Moderna, Inc.（United States）
Gilead Sciences（United States）
Regeneron Pharmaceuticals（United States）
Vertex Pharmaceuticals（United States）
Amgen Inc.（United States）

結論與建議

簡介目錄

Product Code: SQSG35H2018

Biopharmaceutical CMO & CRO Market size was valued at USD 34.31 Billion in 2024 and is poised to grow from USD 36.34 Billion in 2025 to USD 57.48 Billion by 2033, growing at a CAGR of 5.9% during the forecast period (2026-2033).

The biopharmaceutical industry is witnessing significant growth, driven by increasing consumer demand for innovative therapies. Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) have become pivotal in supporting pharmaceutical companies by providing outsourced manufacturing and comprehensive research services, respectively. This trend highlights a shift toward outsourcing resource-intensive processes, including entire biomanufacturing chains, enhancing the demand for contract-based services. The integration of bioprocessing capabilities through mergers and acquisitions allows CMOs to offer streamlined solutions, facilitating accelerated product launches. Investments in integrated manufacturing further bolster this sector, as evidenced by strategic partnerships aimed at improving productivity and efficiency. Overall, CMOs and CROs play a crucial role in the biopharmaceutical landscape, representing over 20% of the pharmaceutical market globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Biopharmaceutical CMO & CRO market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Biopharmaceutical CMO & CRO Market Segments Analysis

Global Biopharmaceutical CMO and CRO Market is segmented by Source, Service Type, Product and region. Based on Source, the market is segmented into Mammalian and Non-mammalian. Based on Service Type, the market is segmented into Contract Manufacturing and Contract Research. Based on Product, the market is segmented into Biologics and Biosimilars. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Biopharmaceutical CMO & CRO Market

The biopharmaceutical industry has experienced a wave of consolidations aimed at enhancing competitiveness and expanding operations within the contract manufacturing and service sectors. As new therapies and innovative bioprocessing techniques emerge, contract bioproducers face mounting pressures to adapt to these changes in market dynamics. To address the diverse needs of stakeholders and consumers, alternative business models are becoming more prevalent. Additionally, the implementation of single-use systems in manufacturing facilities is expected to significantly enhance production capacity. Collectively, these factors indicate strong growth potential for the biopharmaceutical CMO and CRO market, offering new opportunities in the global landscape.

Restraints in the Biopharmaceutical CMO & CRO Market

The biopharmaceutical CMO and CRO market faces several constraints that hinder its growth potential, despite the lucrative profit margins it offers compared to the pharmaceutical CMO sector. A primary challenge lies in the significant investments required for manufacturing facilities and advanced equipment to accelerate biomanufacturing processes. Additionally, many established biopharmaceutical companies are hesitant to fully embrace outsourcing, further limiting market expansion. Moreover, negotiations between CMOs and clients can be complicated due to the intricate regulatory environment and the complexity inherent in these services. Issues surrounding intellectual property rights, confidentiality, and warranties add to the difficulties in client-CMO agreements, creating further barriers to market growth.

Market Trends of the Biopharmaceutical CMO & CRO Market

The biopharmaceutical CMO and CRO market is experiencing a significant upward trend driven by an intensified focus on new product development, expanded R&D activities, and strategic collaborations. As companies face challenges in R&D efficiency and escalating development costs, CMOs and CROs are emerging as pivotal partners, facilitating faster commercial operations. Growth strategies such as geographical expansions, mergers and acquisitions, and enhanced distribution networks are becoming integral to gaining competitive advantages. This evolving landscape underscores the increasing reliance on contract organizations by biopharmaceutical firms, paving the way for sustained market growth and innovation in the biopharmaceutical sector.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technological Advancement

Global Biopharmaceutical CMO & CRO Market Size by Source & CAGR (2026-2033)

Market Overview
Mammalian
Non-mammalian

Global Biopharmaceutical CMO & CRO Market Size by Service Type & CAGR (2026-2033)

Market Overview
Contract Manufacturing
- Process Development
- Downstream
- Upstream
- Fill & Finish Operations
- Analytical & QC Studies
- Packaging
Contract Research
- Oncology
- Inflammation & Immunology
- Cardiology
- Neuroscience
- Others

Global Biopharmaceutical CMO & CRO Market Size by Product & CAGR (2026-2033)

Market Overview
Biologics
- Monoclonal antibodies (MAbs)
- Recombinant Proteins
- Vaccines
- Antisense, RNAi, & Molecular Therapy
- Others
Biosimilars

Global Biopharmaceutical CMO & CRO Market Size & CAGR (2026-2033)

North America (Source, Service Type, Product)
- US
- Canada
Europe (Source, Service Type, Product)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Source, Service Type, Product)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Source, Service Type, Product)
- Brazil
- Rest of Latin America
Middle East & Africa (Source, Service Type, Product)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Lonza Group (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalent (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi Biologics (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Samsung Biologics (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IQVIA (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Syneos Health (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ICON Plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medpace Holdings (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Charles River Laboratories (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PPD (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Labcorp Drug Development (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Parexel International (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PRA Health Sciences (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNTech SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Moderna, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments